Genmab A-S Aktie

195,15 EUR -0,05 EUR -0,03 %

08:01:51

FSE

183,12 CHF +0,39 CHF +0,21 %

12:56:41

BRX

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.12,09 Mrd. EUR

KGV12,21Div. Rendite0,00%

WKN565131

ISINDK0010272202

SymbolGNMSF

Genmab A-S Aktien News

Sortieren:Datum Meistgelesen

28.02.25GlobeNewswireTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

28.02.25GlobeNewswireGrant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab

25.02.25GlobeNewswireCapital Increase in Genmab as a Result of Employee Warrant Exercise

20.02.25GlobeNewswireEPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma

19.02.25GlobeNewswireGenmab to Participate in a Fireside Chat at the 45th Annual TD Cowen Health Care Conference

13.02.25GlobeNewswireNotice to Convene the Annual General Meeting of Genmab A/S

12.02.25GlobeNewswireGenmab Files Annual Report with the U.S. Securities and Exchange Commission

12.02.25GlobeNewswireGenmab Publishes 2024 Annual Report

23.01.25GlobeNewswireGrant of Restricted Stock Units and Warrants to Employees in Genmab

22.01.25GlobeNewswireGenmab Announces Net Sales of DARZALEX® (daratumumab) for 2024

14.01.25ZacksGenmab (GMAB) Upgraded to Buy: Here's What You Should Know

14.01.25ZacksAre Investors Undervaluing Genmab (GMAB) Right Now?

03.01.25GlobeNewswireGenmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference

11.12.24GlobeNewswireGenmab to Hold 2024 R&D Update and ASH Data Review Meeting

09.12.24GlobeNewswireTwo Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma

08.12.24GlobeNewswireInvestigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukem

08.12.24GlobeNewswireInvestigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

03.12.24GlobeNewswireCapital Increase in Genmab as a Result of Employee Warrant Exercise

03.12.24GlobeNewswireTransactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

25.11.24GlobeNewswireGenmab to Present at Citi’s Global Healthcare Conference

21.11.24GlobeNewswireGrant of Restricted Stock Units and Warrants to Employees in Genmab

08.11.24BenzingaA Closer Look at 10 Analyst Recommendations For Genmab

06.11.24GlobeNewswireGenmab Announces Financial Results for the First Nine Months of 2024

05.11.24GlobeNewswireGenmab to Present at Jefferies London Healthcare Conference

05.11.24GlobeNewswireGenmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting

16.10.24ZacksIs the Options Market Predicting a Spike in Genmab (GMAB) Stock?

16.10.24Benzinga12 Analysts Have This To Say About Genmab

15.10.24ZacksIs Genmab (GMAB) Stock Undervalued Right Now?

15.10.24GlobeNewswireGenmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024

08.10.24ZacksDown -14.68% in 4 Weeks, Here's Why Genmab (GMAB) Looks Ripe for a Turnaround

04.10.24GlobeNewswireMajor Shareholder Announcement

26.09.24GlobeNewswireGrant of Restricted Stock Units and Warrants to Employees in Genmab

15.09.24GlobeNewswireInvestigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial

10.09.24GlobeNewswireCapital Increase in Genmab as a Result of Employee Warrant Exercise

09.09.24BenzingaExpert Ratings For Genmab

26.08.24GlobeNewswireGenmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

20.08.24BenzingaDecoding 10 Analyst Evaluations For Genmab

19.08.24GlobeNewswireTEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

16.08.24GlobeNewswireGenmab Announces Changes to its Executive Committee

13.08.24GlobeNewswireTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Genmab A-S News

Genmab A-S News: auf dieser Seite finden Sie alle Genmab A-S News und Nachrichten zur Genmab A-S Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Genmab A-S News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Genmab A-S News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.